Efavirenz metabolism and CNS toxicity in Ugandan children: impact of CYP2B6 genotype and plasma metabolite profiles
IntroductionThe non-nucleoside reverse transcriptase inhibitor efavirenz (EFV) is used in antiretroviral therapy (ART) against HIV. EFV is mainly metabolized by CYP2B6 to 8-hydroxyefavirenz (8-OH-EFV) and to a lesser extent by CYP2A6 to 7-hydroxyefavirenz (7-OH-EFV). Previous studies have only exami...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Frontiers Media S.A.
2026-04-01
|
| Rangatū: | Frontiers in Pharmacology |
| Ngā marau: | |
| Urunga tuihono: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1778383/full |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|